Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Momelotinib in Myelofibrosis, PV, and ET
NCT02124746Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2014
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of momelotinib dihydrochloride in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), polycythemia vera (PV), essential thrombocythemia (ET), sponsored by GSK. Started Apr 2014; status: completed.
02
Drugs
momelotinib dihydrochloride
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)polycythemia vera (PV)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT02124746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02124746.